关于 Editas Medicine, Inc. - Common Stock 公司概况（来自维基百科）

Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

History

Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures. The name was changed to the current "Editas Medicine" two months later. Doudna quit in June 2014 over legal differences concerning intellectual property of Cas9.

In August 2015, the company raised $120 million in Series B funding from Bill Gates and 13 other investors. it went public on 2 February 2016, via a $94 million initial public offering.

Editas entered into a strategic collaboration with Juno Therapeutics in 2015 to create a chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics. Juno was later acquired by Celgene, which was in turn acquired by Bristol Myers Squibb.

The company announced in 2015 that it was planning a clinical trial using CRISPR gene editing techniques to treat Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness. On 30 November 2018, the FDA gave permission to start the trials, under the investigational name EDIT-101 (also known as AGN-151587). In September 2021, a statement from Editas claimed that preliminary results from clinical trials were promising and support clinical benefits of EDIT-101 treatment.

In March 2020, Editas, in partnership with Allergan, was the first to use CRISPR to try to edit DNA inside a person's body (in vivo). As part of the clinical trial, a patient who was nearly blind as a result of Leber's congenital amaurosis received an intravitreal injection containing a harmless virus carrying CRISPR gene-editing instructions. Five months later, Editas reworked its deal with Allergan's owner AbbVie and regained full rights to their range of eye disease treatment therapies, including EDIT-101 for the treatment of LCA10.

In 2019, the company was building new chemistry facilities in Boulder, Colorado.

Katrine Bosley was CEO until 2019, when she was replaced by board member Cynthia Collins. Collins was replaced in 2021 by James Mullen, who had been board chairman. Gilmore O'Neill, former CMO of Sarepta Therapeutics, became CEO on June 1, 2022, with Mullen staying on as executive chairman of the board.

On December 12, 2024, Editas ended the development of reni-cel and laid off 65% of its employees.

Research

Editas works with two different CRISPR nucleases, Cas9 and Cas12a.

EDIT-101 is a CRISPR based gene therapy for treatment of Leber congenital amaurosis, currently in clinical trials.

EDIT-301 is an experimental potential treatment utilizing the firm's CAS 12a editing technology for sickle cell disease and beta-thalassemia. In 2019 the firm reported early success in research on the drug;. In December 2020, it filed an IND application for treatment of sickle cell disease. In January 2021, it said it had received clearance from the FDA for phase 1 safety studies.

== References ==

来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗

Wikidata ↗

EDIT 股票快照价格、市值、P/E、EPS、ROE、负债/权益、52周范围

价格

$3.19

市值

$312M

P/E (TTM)

-1.8

每股收益 (TTM)

$-1.80

营收 (TTM)

$41M

股息收益率

—

ROE

-688.8%

负债/权益

2.1

52周区间

$2 – $5

EDIT 股价图表包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图

10年表现收入、净利润、利润率和每股收益趋势

营收与净利润 $41M

2016-12-31 → 2025-12-31

EPS $-1.80

2019-12-31 → 2025-12-31

自由现金流 $-166M

2016-12-31 → 2025-12-31

利润率 -395.0%

估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？

指标

5年趋势

EDIT

同行中位数

P/E (TTM)

-1.8

17.4

P/S (TTM) (市销率 (TTM))

7.7

52.3

P/B (市净率)

11.4

4.8

EV / EBITDA (企业价值 / EBITDA)

-1.4

—

Price / FCF (股价/自由现金流)

-1.9

—

盈利能力毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)

指标

5年趋势

EDIT

同行中位数

Operating Margin (营业利润率)

-394.9%

—

Net Profit Margin (净利润率)

-395.0%

-670.1%

ROA

-60.6%

-41.1%

ROE

-688.8%

-52.6%

财务健康债务、流动性、偿付能力 — 资产负债表强度

指标

5年趋势

EDIT

同行中位数

Debt / Equity (负债/股东权益比率)

2.1

—

Current Ratio (流动比率)

3.5

7.7

Quick Ratio (速动比率)

3.5

—

成长营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)

指标

5年趋势

EDIT

同行中位数

Revenue YoY (营收同比增长)

25.4%

—

Revenue CAGR 3Y (营收3年复合年增长率)

27.2%

—

Revenue CAGR 5Y (营收5年复合年增长率)

-14.9%

—

每股指标每股收益 (EPS)、每股净资产、每股现金流、每股股息

指标

5年趋势

EDIT

同行中位数

EPS (Diluted) (EPS (稀释))

$-1.80

—

资本效率资产周转率、库存周转率、应收账款周转率

指标

5年趋势

EDIT

同行中位数

EDIT 分析师共识看涨和看跌分析师观点、12个月价格目标、上涨空间

买入 18 位分析师

强烈买入 4 22.2%
买入 8 44.4%
持有 4 22.2%
卖出 2 11.1%
强烈卖出 0 0.0%

12个月价格目标

8 位分析师 · 2026-08-16

中位数 $5.00

现在 $3.19

最低 $1.00

最高 $15.00

中位数目标 $5.00 +57.0%

平均目标 $6.00 +88.4%

收益历史每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期

平均惊喜

-0.03%

期间	EPS Actual	EPS 预期	惊喜
2026年6月30日	$-0.15	$-0.28	0.13%
2026年3月31日	$-0.26	$-0.27	0.01%
2025年12月31日	$-0.06	$-0.26	0.20%
2025年9月30日	$-0.28	$-0.30	0.02%
2025年6月30日	$-0.63	$-0.38	-0.25%
2025年3月31日	$-0.92	$-0.60	-0.32%

同行比较（GICS 子行业）关键指标与行业同行对比

股票代码	市值	P/E	营收同比增长	净利润率	ROE	毛利率
EDIT	$201M	-1.1	25.4%	-395.0%	-688.8%	—
CABA	$220M	-1.0	—	—	-115.5%	—
VSTM	$600M	-2.6	209.1%	-677.6%	-449.2%	—
ZURA	—	—	—	—	—	—
MPLT	$773M	-0.9	—	—	-151.1%	—
OCGN	$422M	-5.6	8.8%	-1537.4%	1488.8%	—
PBYI	$300M	9.8	-0.91%	13.6%	26.5%	—
QTTB	$43M	1.4	—	55.5%	200.3%	—
RZLT	$388M	-4.6	—	—	-56.9%	—
CMPX	$958M	—	—	—	-45.9%	—

完整基本面所有年度指标 — 损益表、资产负债表、现金流量表

损益表 13

EDIT 的年度损益表数据
指标	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	$41M	$32M	$78M	$20M	$26M	$91M	$21M	$32M	$14M	$6M
R&D Expense	$90M	$199M	$178M	$175M	$143M	$158M	$97M	$91M	$83M	$57M
SG&A Expense	$50M	$72M	$70M	$71M	$76M	$68M	$65M	$55M	$51M	$46M
Operating Expenses	$201M	$283M	$247M	$246M	$219M	$226M	$161M	$146M	$134M	$103M
Operating Income	$-160M	$-251M	$-169M	$-226M	$-193M	$-135M	$-141M	$-114M	$-120M	$-97M
Other Non-op	$-2M	$-3.0K	$-2M	$0	$37.0K	$16M	$-137.0K	$328.0K	$587.0K	$-57.0K
Income Tax	$0	$0	$0	$0	$0	·	·	·	·	·
Net Income	$-160M	$-237M	$-153M	$-220M	$-193M	$-116M	$-134M	$-110M	$-120M	$-97M
EPS (Basic)	$-1.80	$-2.88	$-2.02	$-3.21	$-2.85	$-1.98	$-2.68	·	·	·
EPS (Diluted)	$-1.80	$-2.88	$-2.02	$-3.21	$-2.85	$-1.98	$-2.68	·	·	·
Shares (Basic)	88,745,908	82,338,220	75,965,633	68,664,822	67,619,388	58,609,389	49,983,329	·	·	·
Shares (Diluted)	88,745,908	82,338,220	75,965,633	68,664,822	67,619,388	58,609,389	49,983,329	·	·	·
EBITDA	$-160M	$-251M	$-169M	$-226M	$-193M	$-135M	$-141M	$-114M	$-120M	$-97M

资产负债表 24

EDIT 的年度资产负债表数据
指标	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Cash & Equivalents	$147M	$132M	$124M	$142M	$204M	$140M	$238M	$135M	$147M	$185M
Short-term Investments	$0	$138M	$199M	$203M	$296M	$262M	$219M	$234M	$183M	·
Receivables	$15M	$16M	$10M	$5M	$267.0K	$6M	$418.0K	$30.0K	$679.0K	$88.0K
Prepaid Expense	$2M	$3M	$8M	$7M	$7M	$11M	$6M	$6M	$2M	$2M
Current Assets	$164M	$289M	$341M	$357M	$507M	$419M	$464M	$375M	$332M	$187M
PP&E (Net)	$4M	$14M	$12M	$16M	$17M	$14M	$11M	$40M	$39M	$40M
PP&E (Gross)	$32M	$46M	$38M	$37M	$33M	$25M	$18M	$47M	$44M	$42M
Accum. Depreciation	$28M	$32M	$26M	$22M	$16M	$11M	$7M	$7M	$4M	$2M
Other Non-current Assets	$3M	$5M	$9M	$5M	$7M	$5M	$5M	$5M	$2M	$2M
Total Assets	$187M	$342M	$499M	$514M	$677M	$573M	$509M	$420M	$373M	$229M
Accounts Payable	$3M	$5M	$8M	$10M	$5M	$6M	$6M	$5M	$4M	$5M
Accrued Liabilities	$33M	$46M	$35M	$31M	$20M	$24M	$22M	$13M	$11M	$17M
Current Liabilities	$46M	$77M	$63M	$60M	$47M	$58M	$60M	$36M	$37M	$33M
Capital Leases	$12M	$20M	$24M	$33M	$16M	$19M	$23M	$32M	$33M	$35M
Other Non-current Liabilities	$3M	$3M	$2M	$0	·	$28M	$1.0K	$293.0K	$317.0K	$396.0K
Total Liabilities	$159M	$207M	$150M	$154M	$124M	$179M	$246M	$184M	$165M	$95M
Long-term Debt	$59M	$57M	$0	·	·	·	·	·	·	·
Total Debt	$59M	$57M	·	·	·	·	·	·	·	·
Common Stock	$10.0K	$8.0K	$8.0K	$7.0K	$7.0K	$6.0K	$5.0K	$5.0K	$4.0K	$4.0K
Retained Earnings	$-1.63B	$-1.47B	$-1.23B	$-1.08B	$-858M	$-665M	$-549M	$-416M	$-306M	$-186M
AOCI	$0	$268.0K	$198.0K	$-4M	$-493.0K	$-46.0K	$107.0K	$-29.0K	$-76.0K	·
Stockholders' Equity	$27M	$134M	$349M	$361M	$554M	$394M	$262M	$236M	$208M	$135M
Liabilities + Equity	$187M	$342M	$499M	$514M	$677M	$573M	$509M	$420M	$373M	$229M
Shares Outstanding	97,866,996	82,734,696	81,767,263	68,847,382	68,435,257	62,563,457	54,355,798	48,758,951	44,507,960	35,818,131

现金流 10

EDIT 的年度现金流数据
指标	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Stock-based Comp	$10M	$21M	$20M	$29M	$43M	$23M	$27M	$27M	$23M	$17M
Restructuring	·	$12M	$0	$0	·	·	·	·	·	·
Operating Cash Flow	$-165M	$-210M	$-132M	$-177M	$-164M	$-180M	$-41M	$-46M	$-9M	$-50M
CapEx	$607.0K	$9M	$5M	$4M	$8M	$7M	$6M	$5M	$2M	$3M
Investing Cash Flow	$139M	$162M	$-4M	$114M	$-54M	$-141M	$12M	$-53M	$-184M	$-3M
Stock Issued	$43M	$0	$117M	$0	$249M	$204M	$116M	$77M	$154M	$97M
Net Stock Activity	$43M	$0	$117M	·	$249M	$204M	$116M	$77M	$154M	$97M
Financing Cash Flow	$40M	$56M	$118M	$1M	$282M	$224M	$132M	$87M	$155M	$97M
Net Change in Cash	$14M	$8M	$-18M	$-62M	$64M	$-96M	$103M	$-12M	$-39M	$43M
Free Cash Flow	$-166M	$-219M	$-137M	$-181M	$-172M	$-187M	$-47M	$-50M	$-11M	$-53M

盈利能力 5

EDIT 的年度盈利能力数据
指标	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Operating Margin	-394.9%	-777.2%	-216.6%	-1146.3%	-756.1%	-148.6%	-686.4%	-356.1%	·	·
Net Margin	-395.0%	-733.7%	-196.1%	-1118.3%	-753.6%	-127.8%	-651.4%	-344.3%	·	·
EBITDA Margin	-394.9%	-777.2%	-216.6%	-1146.3%	-756.1%	-148.6%	-686.4%	-356.1%	·	·
ROA	-60.6%	-56.4%	-30.2%	-37.0%	-30.8%	-21.4%	-28.8%	-27.7%	-40.0%	-51.3%
ROE	-688.8%	-153.0%	-43.2%	-56.9%	-33.8%	-27.8%	-56.6%	-47.7%	-70.2%	-377.5%

流动性与偿付能力 4

EDIT 的年度流动性与偿付能力数据
指标	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Current Ratio	3.5	3.7	5.4	5.9	10.8	7.2	7.7	10.4	9.1	5.7
Quick Ratio	3.5	3.7	5.3	5.8	10.7	7.0	7.6	10.3	9.0	5.6
Debt / Equity	2.1	0.4	·	·	·	·	·	·	·	·
LT Debt / Equity	2.0	0.4	·	·	·	·	·	·	·	·

效率 2

EDIT 的年度效率数据
指标	趋势	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Asset Turnover		0.2	0.1	0.2	0.0	0.0	0.2	0.0	0.1	·	·
Receivables Turnover		2.6	2.4	10.2	7.3	8.1	28.1	91.7	90.1	·	·

每股 5

EDIT 的年度每股数据
指标	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Book Value / Share	$0.28	$1.62	$4.27	$5.24	$8.09	$6.29	$4.83	$4.84	$4.68	$3.76
Revenue / Share	$0.46	$0.39	$1.03	$0.29	$0.38	·	·	·	·	·
Cash Flow / Share	$-1.86	$-2.55	$-1.74	$-2.58	$-2.42	·	·	·	·	·
Cash / Share	$1.50	$1.59	$1.51	$2.06	$2.97	$2.23	$4.38	$2.76	$3.29	$5.17
EPS (TTM)	$-1.80	$-2.88	$-2.02	$-3.21	$-2.85	$-1.98	$-2.68	·	·	·

增长率 3

EDIT 的年度增长率数据
指标	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Revenue YoY	25.4%	-58.6%	296.3%	-22.8%	-71.9%	·	·	·	·	·
Revenue CAGR 3Y	27.2%	8.2%	-4.9%	·	·	·	·	·	·	·
Revenue CAGR 5Y	-14.9%	·	·	·	·	·	·	·	·	·

估值 (TTM) 14

EDIT 的年度估值 (TTM)数据
指标	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Revenue TTM	$41M	$32M	$78M	$20M	$26M	$91M	$21M	$32M	$14M	$6M
Net Income TTM	$-160M	$-237M	$-153M	$-220M	$-193M	$-116M	$-134M	$-110M	$-120M	$-97M
Market Cap	$201M	$105M	$828M	$611M	$1.82B	$4.39B	$1.61B	$1.11B	$1.37B	$581M
Enterprise Value	$113M	$-107M	·	·	·	·	·	·	·	·
P/E	-1.1	-0.4	-5.0	-2.8	-9.3	-35.4	-11.0	·	·	·
P/S	5.0	3.3	10.6	31.0	71.1	48.3	78.4	34.7	99.6	96.0
P/B	7.4	0.8	2.4	1.7	3.3	11.1	6.1	4.7	6.6	4.3
P / Tangible Book	7.4	0.8	2.4	1.7	3.3	11.1	·	·	·	·
P / Cash Flow	-1.2	-0.5	-6.3	-3.4	-11.1	-24.4	-39.6	-24.3	-145.2	-11.6
P / FCF	-1.2	-0.5	-6.1	-3.4	-10.6	-23.5	-34.4	-22.0	-119.2	-10.9
EV / EBITDA	-0.7	0.4	·	·	·	·	·	·	·	·
EV / FCF	-0.7	0.5	·	·	·	·	·	·	·	·
EV / Revenue	2.8	-3.3	·	·	·	·	·	·	·	·
Earnings Yield	-87.8%	-226.8%	-19.9%	-36.2%	-10.7%	-2.8%	-9.0%	·	·	·

损益表 12

EDIT 的季度损益表数据
指标	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue	$12M	$3M	$25M	$8M	$4M	$5M	$31M	$61.0K	$513.0K	$1M	$60M	$5M	$3M	$10M	$7M	$42.0K
R&D Expense	$20M	$18M	$27M	$20M	$16M	$27M	$49M	$48M	$54M	$49M	$70M	$41M	$30M	$38M	$52M	$41M
SG&A Expense	$12M	$10M	$11M	$12M	$13M	$13M	$16M	$18M	$18M	$19M	$14M	$15M	$17M	$23M	$18M	$16M
Operating Expenses	$30M	$28M	$32M	$32M	$55M	$81M	$77M	$66M	$72M	$68M	$84M	$55M	$47M	$61M	$70M	$58M
Operating Income	$-19M	$-25M	$-8M	$-25M	$-52M	$-76M	$-47M	$-66M	$-72M	$-67M	$-24M	$-50M	$-44M	$-51M	$-63M	$-58M
Other Non-op	$17.0K	$-113.0K	$-5.0K	$-1.0K	$-2M	$-425.0K	$-3.0K	$-5.0K	$-1.0K	$6.0K	$-13.0K	$0	$-7.0K	$-2M	$-2.0K	$1.0K
Net Income	$-18M	$-25M	$-6M	$-25M	$-53M	$-76M	$-45M	$-62M	$-68M	$-62M	$-19M	$-45M	$-40M	$-49M	$-61M	$-56M
EPS (Basic)	$-0.15	$-0.26	$0.03	$-0.28	$-0.63	$-0.92	$-0.55	$-0.75	$-0.82	$-0.76	$-0.20	$-0.55	$-0.56	$-0.71	$-0.88	$-0.81
EPS (Diluted)	$-0.15	$-0.26	$0.03	$-0.28	$-0.63	$-0.92	$-0.55	$-0.75	$-0.82	$-0.76	$-0.20	$-0.55	$-0.56	$-0.71	$-0.88	$-0.81
Shares (Basic)	119,294,615	97,879,343	-168,811,755	90,090,397	84,412,200	83,055,066	-164,396,186	82,485,199	82,310,368	81,938,839	-145,983,475	81,648,250	71,376,678	68,924,180	-137,197,139	68,736,125
Shares (Diluted)	119,294,615	97,879,343	-168,811,755	90,090,397	84,412,200	83,055,066	-164,396,186	82,485,199	82,310,368	81,938,839	-145,983,475	81,648,250	71,376,678	68,924,180	-137,197,139	68,736,125
EBITDA	$-19M	$-25M	·	$-25M	$-52M	$-76M	·	$-66M	$-72M	$-67M	·	$-50M	$-44M	$-51M	·	$-58M

资产负债表 24

EDIT 的季度资产负债表数据
指标	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Cash & Equivalents	$182M	$124M	$147M	$166M	$139M	$139M	$132M	$96M	$64M	$69M	$124M	$83M	$221M	$129M	$142M	$211M
Short-term Investments	$30M	·	$0	$0	$40M	$82M	$138M	$169M	$215M	$227M	$199M	$267M	$211M	$189M	·	$209M
Receivables	$3M	$3M	$15M	$8M	$588.0K	$510.0K	$16M	$126.0K	$244.0K	$245.0K	$10M	$2M	$2M	$242.0K	·	$120.0K
Prepaid Expense	$4M	$2M	$2M	$3M	$4M	$3M	$3M	$6M	$7M	$9M	$8M	$7M	$7M	$6M	·	$7M
Current Assets	$218M	$128M	$164M	$177M	$183M	$225M	$289M	$271M	$286M	$306M	$341M	$359M	$441M	$324M	·	$427M
PP&E (Net)	$3M	$3M	$4M	$4M	$5M	$8M	$14M	$15M	$14M	$13M	$12M	$12M	$13M	$13M	·	$15M
PP&E (Gross)	$29M	$29M	$32M	$32M	$31M	$36M	$46M	$46M	$43M	$41M	$38M	$37M	$36M	$35M	·	$36M
Accum. Depreciation	$27M	$26M	$28M	$28M	$27M	$28M	$32M	$31M	$29M	$28M	$26M	$25M	$23M	$22M	·	$20M
Other Non-current Assets	$3M	$3M	$3M	$3M	$4M	$4M	$5M	$5M	$8M	$9M	$9M	$6M	$5M	$7M	·	$8M
Total Assets	$237M	$149M	$187M	$202M	$211M	$264M	$342M	$328M	$385M	$440M	$499M	$505M	$542M	$464M	·	$531M
Accounts Payable	$5M	$4M	$3M	$3M	$7M	$5M	$5M	$12M	$14M	$8M	$8M	$10M	$8M	$9M	·	$7M
Accrued Liabilities	$17M	$21M	$33M	$48M	$48M	$47M	$46M	$29M	$28M	$31M	$35M	$30M	$28M	$32M	·	$19M
Current Liabilities	$68M	$40M	$46M	$62M	$66M	$73M	$77M	$72M	$74M	$66M	$63M	$59M	$55M	$57M	·	$42M
Capital Leases	$9M	$11M	$12M	$14M	$15M	$18M	$20M	$22M	$21M	$22M	$24M	$25M	$27M	$29M	·	$9M
Other Non-current Liabilities	$2M	$3M	$3M	$5M	$5M	$6M	$3M	$3M	$4M	$3M	$2M	·	·	·	·	·
Total Liabilities	$132M	$145M	$159M	$188M	$191M	$201M	$207M	$152M	$153M	$146M	$150M	$144M	$142M	$147M	·	$116M
Long-term Debt	$56M	$55M	$59M	$59M	$57M	$55M	$57M	·	·	·	$0	·	·	·	·	·
Total Debt	$56M	$55M	·	$59M	$57M	$55M	·	·	·	·	·	·	·	·	·	·
Common Stock	$15.0K	$10.0K	$10.0K	$9.0K	$9.0K	$8.0K	$8.0K	$8.0K	$8.0K	$8.0K	$8.0K	$8.0K	$8.0K	$7.0K	·	$7.0K
Retained Earnings	$-1.67B	$-1.65B	$-1.63B	$-1.62B	$-1.60B	$-1.54B	$-1.47B	$-1.42B	$-1.36B	$-1.29B	$-1.23B	$-1.21B	$-1.17B	$-1.13B	·	$-1.02B
AOCI	$-6.0K	$0	$0	$0	$15.0K	$88.0K	$268.0K	$522.0K	$-442.0K	$-326.0K	$198.0K	$-1M	$-2M	$-2M	·	$-4M
Stockholders' Equity	$105M	$4M	$27M	$13M	$19M	$62M	$134M	$176M	$232M	$294M	$349M	$360M	$400M	$317M	$361M	$415M
Liabilities + Equity	$237M	$149M	$187M	$202M	$211M	$264M	$342M	$328M	$385M	$440M	$499M	$505M	$542M	$464M	·	$531M
Shares Outstanding	97,866,996	97,866,996	97,866,996	93,264,421	87,388,425	83,709,536	82,734,696	82,538,624	82,429,514	82,234,951	81,767,263	81,668,796	81,616,909	68,993,591	·	68,761,729

现金流 10

EDIT 的季度现金流数据
指标	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Stock-based Comp	$2M	$2M	$2M	$2M	$3M	$3M	$4M	$5M	$5M	$8M	$5M	$5M	$5M	$5M	$5M	$6M
Restructuring	·	·	·	·	·	$53M	·	·	·	·	·	·	·	·	·	·
Operating Cash Flow	$-30M	$-23M	$-36M	$-31M	$-50M	$-48M	$-51M	$-53M	$-57M	$-50M	$-22M	$-35M	$-39M	$-36M	$-42M	$-48M
CapEx	$106.0K	$92.0K	$60.0K	$433.0K	$0	$114.0K	$540.0K	$3M	$3M	$2M	$1M	$239.0K	$1M	$2M	$624.0K	$614.0K
Investing Cash Flow	$-30M	$64.0K	$58.0K	$40M	$43M	$56M	$31M	$84M	$52M	$-5M	$63M	$-103M	$13M	$23M	$-28M	$89M
Stock Issued	$117M	$0	$17M	$17M	$7M	$1M	$0	$0	$0	$0	$0	$0	·	·	$0	·
Net Stock Activity	·	$0	·	·	·	$1M	·	·	·	·	·	·	·	·	·	·
Financing Cash Flow	$118M	$0	$17M	$17M	$7M	$-1M	$56M	$0	$322.0K	$192.0K	$514.0K	$0	$118M	$0	$619.0K	$80.0K
Net Change in Cash	$58M	$-23M	$-19M	$26M	$-150.0K	$7M	$36M	$31M	$-5M	$-54M	$41M	$-138M	$92M	$-13M	$-69M	$41M
Free Cash Flow	·	$-23M	·	·	·	$-48M	·	·	·	$-52M	·	·	·	$-38M	·	·

盈利能力 5

EDIT 的季度盈利能力数据
指标	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Operating Margin	-156.1%	-883.2%	·	-325.4%	-1440.6%	-1635.1%	·	-107649.2%	-14016.2%	-5902.3%	·	-940.1%	-1527.3%	-517.3%	·	-136952.4%
Net Margin	-153.3%	-882.4%	·	-333.0%	-1487.8%	-1633.5%	·	-101870.5%	-13178.8%	-5458.1%	·	-843.7%	-1395.6%	-497.8%	·	-132681.0%
EBITDA Margin	-156.1%	-883.2%	·	-325.4%	-1440.6%	-1635.1%	·	-107649.2%	-14016.2%	-5902.3%	·	-940.1%	-1527.3%	-517.3%	·	-136952.4%
ROA	-8.1%	-12.1%	·	-9.5%	-17.9%	-21.6%	·	-14.9%	-14.6%	-13.7%	·	-8.7%	-7.2%	-9.0%	·	-8.9%
ROE	-29.3%	-74.8%	·	-26.6%	-42.4%	-42.6%	·	-23.2%	-21.4%	-20.2%	·	-11.6%	-9.3%	-11.8%	·	-11.1%

流动性与偿付能力 4

EDIT 的季度流动性与偿付能力数据
指标	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Current Ratio	3.2	3.2	·	2.9	2.8	3.1	·	3.7	3.9	4.6	·	6.1	8.1	5.7	·	10.1
Quick Ratio	3.1	3.2	·	2.8	2.7	3.0	·	3.7	3.8	4.5	·	6.0	8.0	5.6	·	9.9
Debt / Equity	0.5	12.4	·	4.4	3.0	0.9	·	·	·	·	·	·	·	·	·	·
LT Debt / Equity	0.5	10.7	·	4.0	2.7	0.8	·	·	·	·	·	·	·	·	·	·

效率 2

EDIT 的季度效率数据
指标	趋势	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Asset Turnover		0.1	0.0	·	0.0	0.0	0.0	·	0.0	0.0	0.0	·	0.0	0.0	0.0	·	0.0
Receivables Turnover		7.2	1.8	·	1.8	8.6	12.3	·	0.0	0.4	4.7	·	4.2	1.9	12.2	·	0.2

每股 5

EDIT 的季度每股数据
指标	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Book Value / Share	$1.08	$0.04	·	$0.14	$0.22	$0.75	·	$2.13	$2.81	$3.58	·	$4.41	$4.90	$4.60	·	$6.03
Revenue / Share	$0.10	$0.03	·	$0.08	$0.04	$0.06	·	$0.00	$0.01	$0.01	·	$0.07	$0.04	$0.14	·	$0.00
Cash Flow / Share	·	$-0.24	·	·	·	$-0.58	·	·	·	$-0.61	·	·	·	$-0.52	·	·
Cash / Share	$1.86	$1.26	·	$1.78	$1.59	$1.66	·	$1.16	$0.78	$0.84	·	$1.01	$2.71	$1.87	·	$3.06
EPS (TTM)	$-1.32	$-2.09	·	$-2.58	$-3.12	$-3.25	·	$-2.88	$-2.69	$-2.58	·	$-2.63	$-2.86	$-3.04	·	$-2.90

估值 (TTM) 14

EDIT 的季度估值 (TTM)数据
指标	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue TTM	$26M	$19M	·	$16M	$9M	$6M	·	$7M	$10M	$19M	·	$18M	$19M	$23M	·	$19M
Net Income TTM	$-122M	$-179M	·	$-217M	$-259M	$-268M	·	$-237M	$-215M	$-196M	·	$-190M	$-199M	$-209M	·	$-199M
Market Cap	$317M	$242M	·	$324M	$192M	$97M	·	$281M	$385M	$610M	·	$637M	$672M	$500M	·	$842M
Enterprise Value	$161M	$173M	·	$217M	$70M	$-69M	·	·	·	·	·	·	·	·	·	·
P/E	-2.5	-1.2	·	-1.3	-0.7	-0.4	·	-1.2	-1.7	-2.9	·	-3.0	-2.9	-2.4	·	-4.2
P/S	12.3	13.0	·	20.4	21.8	15.3	·	40.0	39.0	31.8	·	35.2	35.1	21.7	·	43.4
P/B	3.0	54.8	·	24.1	10.0	1.6	·	1.6	1.7	2.1	·	1.8	1.7	1.6	·	2.0
P / Tangible Book	3.0	54.8	·	24.1	10.0	1.6	·	1.6	1.7	2.1	·	1.8	1.7	1.6	·	2.0
P / Cash Flow	·	-10.5	·	·	·	-2.0	·	·	·	-12.2	·	·	·	-14.0	·	·
P / FCF	·	-10.4	·	·	·	-2.0	·	·	·	-11.8	·	·	·	-13.3	·	·
EV / EBITDA	-8.7	-6.9	·	-8.8	-1.4	0.9	·	·	·	·	·	·	·	·	·	·
EV / FCF	·	-7.5	·	·	·	1.4	·	·	·	·	·	·	·	·	·	·
EV / Revenue	6.2	9.3	·	13.7	8.0	-10.9	·	·	·	·	·	·	·	·	·	·
Earnings Yield	-40.7%	-84.6%	·	-74.4%	-141.8%	-280.2%	·	-84.5%	-57.6%	-34.8%	·	-33.7%	-34.8%	-41.9%	·	-23.7%

财务报表损益表、资产负债表、现金流量表 — 年度，近5年

损益表

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
收入	$41M	$32M	$78M	$20M	$26M
营业利润率 %	-394.9%	-777.2%	-216.6%	-1146.3%	-756.1%
净收入	$-160M	$-237M	$-153M	$-220M	$-193M
稀释后每股收益 (EPS)	$-1.80	$-2.88	$-2.02	$-3.21	$-2.85

资产负债表

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
负债/股东权益比率	2.1	0.4	—	—	—
流动比率	3.5	3.7	5.4	5.9	10.8
速动比率	3.5	3.7	5.3	5.8	10.7

现金流

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
自由现金流	$-166M	$-219M	$-137M	$-181M	$-172M

我的指标您的个人关注列表 — 来自完整基本面的选定行

📊

选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。

您的选择已保存，并会跟随您浏览所有股票。

机构持有人 (13F) 240 家申报者 · $327.2M 总计 · 截至 2026年6月30日

在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。

机构活动 — Q2 2026 与上一季度对比

新仓位	已退出持仓	增加	减少	净股数变动
41 (+2 与上一季度对比)	22 (-4 与上一季度对比)	76 (+20 与上一季度对比)	42 (-9 与上一季度对比)	+75.4M

与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。

机构	价值	股份	% 已追踪的13F	类型
TCG Crossover Management, LLC	$36000000	11111111	11.00%	股份
RA CAPITAL MANAGEMENT, L.P.	$28800360	8889000	8.80%	股份
Commodore Capital LP	$28800360	8889000	8.80%	股份
ADAR1 Capital Management, LLC	$28800360	8889000	8.80%	股份
VANGUARD CAPITAL MANAGEMENT LLC	$19897929	6141336	6.08%	股份
Paradigm Biocapital Advisors LP	$18100665	5586625	5.53%	股份
Opaleye Management Inc.	$12512653	3861930	3.82%	股份
VANGUARD PORTFOLIO MANAGEMENT LLC	$11658618	3598339	3.56%	股份
Woodline Partners LP	$11519810	3555497	3.52%	股份
Vivo Capital, LLC	$11519010	3555250	3.52%	股份
GordonMD Global Investments LP	$10131480	3127000	3.10%	股份
RENAISSANCE TECHNOLOGIES LLC	$7999298	2468919	2.45%	股份
Logos Global Management LP	$7199280	2222000	2.20%	股份
GEODE CAPITAL MANAGEMENT, LLC	$7134030	2201290	2.18%	股份
STATE STREET CORP	$7101442	2191803	2.17%	股份
GOLDMAN SACHS GROUP INC	$6763843	2087606	2.07%	股份
TWO SIGMA INVESTMENTS, LP	$4318842	1332976	1.32%	股份
Seven Fleet Capital Management LP	$4310820	1330500	1.32%	股份
RAYMOND JAMES FINANCIAL INC	$4201156	1296653	1.28%	股份
MARSHALL WACE, LLP	$4044048	1248163	1.24%	股份
D. E. Shaw & Co., Inc.	$3715178	1146660	1.14%	股份
KENNEDY CAPITAL MANAGEMENT LLC	$3344111	1032133	1.02%	股份
MACKENZIE FINANCIAL CORP	$2844856	878042	0.87%	股份
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$2812424	868032	0.86%	股份
Nantahala Capital Management, LLC	$2762748	852700	0.84%	股份
TWO SIGMA ADVISERS, LP	$2509405	1224100	0.77%	股份
VANGUARD FIDUCIARY TRUST CO	$2407158	742950	0.74%	股份
BlackRock, Inc.	$1813920	559852	0.55%	股份
MILLENNIUM MANAGEMENT LLC	$1616750	498997	0.49%	股份
Susquehanna Portfolio Strategies, LLC	$1545801	477099	0.47%	股份
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$1521180	469500	0.46%	买入期权
Eversept Partners, LP	$1486541	458809	0.45%	股份
Casdin Capital, LLC	$1441800	445000	0.44%	股份
PEAK6 LLC	$1346029	415441	0.41%	股份
DIADEMA PARTNERS LP	$1296000	400000	0.40%	买入期权
BIT Capital GmbH	$1056240	326000	0.32%	股份
Cubist Systematic Strategies, LLC	$994094	286482	0.30%	股份
LOS ANGELES CAPITAL MANAGEMENT LLC	$878642	271186	0.27%	股份
BANK OF AMERICA CORP /DE/	$751119	231827	0.23%	股份
LPL Financial LLC	$748813	231115	0.23%	股份
Erste Asset Management GmbH	$736000	230000	0.22%	股份
IEQ CAPITAL, LLC	$705623	217785	0.22%	股份
Walleye Capital LLC	$595703	183859	0.18%	股份
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$558900	172500	0.17%	卖出期权
CITADEL ADVISORS LLC	$557604	172100	0.17%	卖出期权
DAFNA Capital Management LLC	$552323	170470	0.17%	股份
Mariner, LLC	$548500	169291	0.17%	股份
Green Alpha Advisors, LLC	$505589	156046	0.15%	股份
PEAK6 LLC	$497340	153500	0.15%	买入期权
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	$490555	151406	0.15%	股份
BARCLAYS PLC	$476030	146923	0.15%	股份
ALLIANCEBERNSTEIN L.P.	$464187	187930	0.14%	股份
JACOBS LEVY EQUITY MANAGEMENT, INC	$445030	137355	0.14%	股份
BRIDGEWAY CAPITAL MANAGEMENT, LLC	$408240	126000	0.12%	股份
Point72 Asset Management, L.P.	$405758	125234	0.12%	股份
RHUMBLINE ADVISERS	$380421	117417	0.12%	股份
JPMORGAN CHASE & CO	$376528	117665	0.12%	股份
JANE STREET GROUP, LLC	$374473	115578	0.11%	股份
FMR LLC	$348384	107526	0.11%	股份
HSBC HOLDINGS PLC	$314481	97062	0.10%	股份
Bank of New York Mellon Corp	$309378	95487	0.09%	股份
WELLINGTON MANAGEMENT GROUP LLP	$303462	93661	0.09%	股份
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$300818	92845	0.09%	股份
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	$300226	92094	0.09%	股份
AMERICAN CENTURY COMPANIES INC	$300011	92596	0.09%	股份
CWM, LLC	$259352	105001	0.08%	股份
MORGAN STANLEY	$237324	73248	0.07%	股份
CITADEL ADVISORS LLC	$229392	70800	0.07%	买入期权
OSAIC HOLDINGS, INC.	$222928	68806	0.07%	股份
SEI INVESTMENTS CO	$221188	68268	0.07%	股份
Nuveen, LLC	$221188	68268	0.07%	股份
Joel Isaacson & Co., LLC	$220787	68144	0.07%	股份
JANE STREET GROUP, LLC	$218376	67400	0.07%	卖出期权
SIMPLEX TRADING, LLC	$207275	63974	0.06%	股份
MetLife Investment Management, LLC	$182140	56216	0.06%	股份
CITIGROUP INC	$182052	56189	0.06%	股份
CITADEL ADVISORS LLC	$173923	53680	0.05%	股份
MML INVESTORS SERVICES, LLC	$168765	52088	0.05%	股份
GROUP ONE TRADING LLC	$163131	50349	0.05%	股份
Creative Planning	$147653	45572	0.05%	股份
China Universal Asset Management Co., Ltd.	$143934	44424	0.04%	股份
WINTON GROUP Ltd	$141588	43700	0.04%	股份
Vanguard Global Advisers, LLC	$138876	42863	0.04%	股份
CANADA PENSION PLAN INVESTMENT BOARD	$137376	42400	0.04%	股份
Graham Capital Management, L.P.	$134369	41472	0.04%	股份
Quinn Opportunity Partners LLC	$129600	40000	0.04%	股份
Invesco Ltd.	$128178	39561	0.04%	股份
Vanguard Personalized Indexing Management, LLC	$124108	38305	0.04%	股份
MERCER GLOBAL ADVISORS INC /ADV	$121967	37644	0.04%	股份
Balyasny Asset Management L.P.	$121947	37638	0.04%	股份
AXQ CAPITAL, LP	$118104	36452	0.04%	股份
Nuveen Asset Management, LLC	$113934	89712	0.03%	股份
SCS Capital Management LLC	$113400	35000	0.03%	股份
Police & Firemen's Retirement System of New Jersey	$109749	33873	0.03%	股份
Thrive Wealth Management, LLC	$108540	33500	0.03%	股份
TWO SIGMA SECURITIES, LLC	$107367	33138	0.03%	股份
INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC	$102359	31207	0.03%	股份
CAPTRUST FINANCIAL ADVISORS	$98159	30296	0.03%	股份
HORIZON KINETICS ASSET MANAGEMENT LLC	$89683	27680	0.03%	股份
MANUFACTURERS LIFE INSURANCE COMPANY, THE	$88339	27265	0.03%	股份

公司内部人士 32 位内幕人士 · 13 位高管 · 15 位董事

内部人士	角色	上次活动	持股数量	卖出 12个月	净额 12个月
Gilmore Neil O'Neill	CEO	2026年6月3日 S	248313	1	$-41543
MULLEN JAMES C	CEO	2022年1月3日 S	75898	0	$0
Cynthia Collins	CEO	2021年2月9日 S	43760	0	$0
Katrine Bosley	President and CEO	2019年1月8日 S	1204966	0	$0
Michelle Robertson	Chief Financial Officer	2022年1月11日 S	31462	0	$0
Andrew A. F. Hack	Chief Financial Officer	2019年2月4日 M	0	0	$0
Linda Burkly	EVP, CHIEF SCIENTIFIC OFFICER	2026年7月28日 S	62369	2	$-15133
Bruce Eaton	EVP, Chief Business Officer	2021年12月22日 A	31498	0	$0
Lisa Anne Michaels	EVP/Chief Medical Officer	2021年12月22日 A	22675	0	$0
Mark S Shearman	EVP, Chief Scientific Officer	2021年12月22日 A	41785	0	$0
Judith R Abrams	Chief Medical Officer	2019年10月28日 A	25000	0	$0
Vickesh Myer	Chief Technology Officer	2019年3月18日 M	0	0	$0
Gerald Frank Cox	Chief Medical Officer	2018年2月7日 A	4000	0	$0
Elliott M. Levy	董事	2026年6月17日 A	—	0	$0
David Scadden	董事	2026年6月17日 A	—	0	$0
Bernadette Connaughton	董事	2026年6月17日 A	—	0	$0
Jessica Hopfield	董事	2026年6月17日 A	22700	0	$0
Andrew Hirsch	董事	2026年6月17日 A	—	0	$0
Emma Reeve	董事	2021年9月3日 A	—	0	$0
Meeta Chatterjee	董事	2021年6月3日 A	—	0	$0
Boris Nikolic	董事	2018年6月15日 A	35000	0	$0
Douglas G. Cole	董事	2017年8月17日 J	3171	0	$0
Kevin Bitterman	董事	2017年6月15日 A	2797144	0	$0
Alexis Borisy	董事	2017年6月15日 A	0	0	$0
John Mendlein	董事	2017年6月15日 A	—	0	$0
Kevin P Starr	10% 所有者	2016年9月6日 S	0	0	$0
bng0, LLC	10% 所有者	2016年2月8日 C	2649572	0	$0
Patrick Thomas Ellinor II	—	2026年8月6日 A	—	0	$0
Amy Parison	—	2026年8月3日 S	14292	2	$-3002
Akshay Vaishnaw	—	2021年6月3日 A	—	0	$0
Charles Albright	—	2020年12月15日 M	24907	0	$0
Alexandra Glucksmann	—	2017年3月15日 M	117788	0	$0

来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖

激进投资者及 5%+ 股东 1 持仓

提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。

申报人	已申报	持股	状态	目的	申报
Polaris Venture Partners VI, L.P. (“PVP VI”), Polaris Venture Founders’ Fund VI, L.P. (“PVPFF VI”), Polaris Venture Management Co. VI, L.L.C. (“PVM VI”), Jonathan A. Flint (“Flint”), Terrance G. McGuire (“McGuire”), Brian Chee (“Chee”), David Barrett (“Barrett”), Amir Nashat (“Nashat”), Bryce Youngren (“Youngren”) ×4 申报	2017年9月18日	—	初始申报	—	SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ETF持仓由 28 只交易所交易基金持有

权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。

基金	权重	单位	截至	来源
QQQS · Invesco Exchange-Traded Fund Trus...	0.41%	32319 SH	2026年8月8日	每日
GNOM · Global X Funds	0.34%	54725 NS	2026年5月31日	N-PORT
IWC · iShares Trust	0.07%	341978 SH	2026年8月8日	每日
IBB · iShares Trust	0.03%	1035067 SH	2026年8月8日	每日
IBBQ · Invesco Exchange-Traded Fund Trus...	0.03%	8268 SH	2026年8月8日	每日
VTWG · VANGUARD SCOTTSDALE FUNDS	0.02%	96927 SH	2026年8月8日	每日
BIB · ProShares Trust	0.02%	3611 NS	2026年5月31日	N-PORT
TMFX · RBB Fund, Inc.	0.02%	1527 NS	2026年5月31日	N-PORT
IWO · iShares Trust	0.02%	823535 SH	2026年8月8日	每日
PRFZ · Invesco Exchange-Traded Fund Trust	0.01%	118938 SH	2026年8月8日	每日
VTWO · VANGUARD SCOTTSDALE FUNDS	0.01%	575834 SH	2026年8月8日	每日
VHT · VANGUARD WORLD FUND	0.01%	461967 SH	2026年8月8日	每日
IWM · iShares Trust	0.01%	2583050 SH	2026年8月8日	每日
RSSL · Global X Funds	0.01%	42610 NS	2026年4月30日	N-PORT
ITWO · ProShares Trust	0.01%	4633 NS	2026年5月31日	N-PORT
SCHA · SCHWAB STRATEGIC TRUST	0.01%	476309 NS	2026年5月31日	N-PORT
UWM · ProShares Trust	0.01%	3622 NS	2026年5月31日	N-PORT
AVSC · AMERICAN CENTURY ETF TRUST	0.00%	32379 NS	2026年5月31日	N-PORT
URTY · ProShares Trust	0.00%	3660 NS	2026年5月31日	N-PORT
IWN · iShares Trust	0.00%	120119 SH	2026年8月8日	每日
HDG · ProShares Trust	0.00%	92 NS	2026年5月31日	N-PORT
MSSM · MORGAN STANLEY PATHWAY FUNDS	0.00%	2922 NS	2026年5月31日	N-PORT
SCHB · SCHWAB STRATEGIC TRUST	0.00%	96350 NS	2026年5月31日	N-PORT
IWV · iShares Trust	0.00%	19020 SH	2026年8月8日	每日
VXF · VANGUARD INDEX FUNDS	0.00%	1100306 SH	2026年8月8日	每日
VTI · VANGUARD INDEX FUNDS	0.00%	4890144 SH	2026年8月8日	每日
VTWV · VANGUARD SCOTTSDALE FUNDS	0.00%	9046 SH	2026年8月8日	每日
VTHR · VANGUARD SCOTTSDALE FUNDS	0.00%	7608 SH	2026年8月8日	每日

关于 Editas Medicine, Inc. - Common Stock 公司概况（来自维基百科）

History

Research

EDIT 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围

EDIT 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图

移动平均线和叠加层

成交量

振荡器

动量和趋势

10年表现 收入、净利润、利润率和每股收益趋势

估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？

盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)

财务健康 债务、流动性、偿付能力 — 资产负债表强度

成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)

每股指标 每股收益 (EPS)、每股净资产、每股现金流、每股股息

资本效率 资产周转率、库存周转率、应收账款周转率

EDIT 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间

12个月价格目标

收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期

同行比较（GICS 子行业） 关键指标与行业同行对比

完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表

财务报表 损益表、资产负债表、现金流量表 — 年度，近5年

我的指标 您的个人关注列表 — 来自完整基本面的选定行

机构持有人 (13F) 240 家申报者 · $327.2M 总计 · 截至 2026年6月30日

公司内部人士 32 位内幕人士 · 13 位高管 · 15 位董事

激进投资者及 5%+ 股东 1 持仓

ETF持仓 由 28 只交易所交易基金持有

EDIT 股票快照价格、市值、P/E、EPS、ROE、负债/权益、52周范围

EDIT 股价图表包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图

10年表现收入、净利润、利润率和每股收益趋势

盈利能力毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)

财务健康债务、流动性、偿付能力 — 资产负债表强度

成长营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)

每股指标每股收益 (EPS)、每股净资产、每股现金流、每股股息

资本效率资产周转率、库存周转率、应收账款周转率

EDIT 分析师共识看涨和看跌分析师观点、12个月价格目标、上涨空间

收益历史每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期

同行比较（GICS 子行业）关键指标与行业同行对比

完整基本面所有年度指标 — 损益表、资产负债表、现金流量表

财务报表损益表、资产负债表、现金流量表 — 年度，近5年

我的指标您的个人关注列表 — 来自完整基本面的选定行

ETF持仓由 28 只交易所交易基金持有